C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days
WATERTOWN, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to...
WATERTOWN, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to...
Presentation of data from ReSPECT-GBM Phase 1/2a and Phase 2b trials expected second half of 2023AUSTIN, Texas, April 19, 2023...
Enjoy a Blast of Summer Nostalgia with Good Supply’s New Product Lineup Now Available Across CanadaTORONTO, April 19, 2023 (GLOBE...
Novel Technology Identified Genes that Promote T Cell Exhaustion, and which are Unique from PD-1/PD-L1 Checkpoint Pathway Engineered CAR-T Cells...
Investment will further accelerate the development of EPI-321VANCOUVER, British Columbia, April 18, 2023 (GLOBE NEWSWIRE) -- SOLVE FSHD, a venture-philanthropic...
H1’s new brand strategy and website recognized by HITMC for its visual appeal and stellar contentNEW YORK, April 18, 2023...
ERAS-601, a potential best-in-class SHP2 inhibitor, blocks oncogenic signal transduction to delay onset of therapeutic resistance Combination was well-tolerated; supports...
Recovery TeamLink™ provides newfound transparency and coordination with the teams that are traveling to recover organs for transplantBALTIMORE, April 18,...
Philips 2023 FHI: Healthcare leaders focused on staff shortages Philips 2023 FHI: Healthcare leaders want to step up AI investments...
Unlocking enterprise-wide, actionable insights can help to improve outcomes April 17, 2023 Amsterdam, the Netherlands and Chicago, USA – Royal...
New domestic supply source to help address critical shortage of medical radioisotopesProprietary platform will be capable of generating up to 12 different...
Scilex Holding Company and CH Trading Group and AD Ports Group Master Distribution Agreement Signing CeremonyDesignated Territories will include the...
Preclinical data supports targeting ITK as a new approach for cancer immunotherapy Novel mechanism of action modulates T cell differentiation...
Data suggest Cyclin E1 plays a critical role in high proportion of multiple tumor types including platinum-resistant ovarian cancer Company...
Hutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury after StrokeAUSTIN, Texas, April 17, 2023...
Preclinical data describes a novel EGFR-sparing, brain-penetrant ErbB2 inhibitor active against key oncogenic ErbB2 mutations In vivo characterization shows a...
Net annualized savings from initiatives expected to be approximately $30 million beginning in 2024 FRANKLIN, Tenn., April 17, 2023 (GLOBE...
Media Release Soft tissue sarcoma, an orphan disease, represents a high unmet medical need with a poor prognosisFirst time efti...
INB-300, a gamma-delta T cell chimeric antigen receptor (CAR) platform, demonstrated the ability to target cancer cells while sparing healthy...
IK-930 is a potent Hippo pathway inhibitor that selectively binds TEAD1 and broadly represses oncogenic TEAD signaling IK-930’s differentiated paralog...